Company intelligence / Profile preview
Impel Pharmaceuticals
Seattle, Washington, United Statesimpelpharma.com ↗
- Ownership
- Public · IMPL
- Employees
- ~160
- Development stage
- Commercial
01
Overview
Impel Pharmaceuticals developed the proprietary POD® intranasal drug delivery platform to enable rapid, consistent absorption of therapeutics through the upper nasal space. Its lead product, Trudhesa® nasal spray delivering dihydroergotamine mesylate, was FDA-approved in September 2021 for acute migraine. Clinical studies demonstrated injection-like absorption and rapid onset of action. The company has faced financial challenges and entered Chapter 11 bankruptcy proceedings in December 2023 while seeking a buyer to continue operations.[4][7][9]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
No major disclosed pharma partnerships; open to licensing/collaboration opportunities per corporate statements
04
Financials
- Market cap
- $956K
- Total revenue
- $5M
- Enterprise value
- $115.5M
Beyond the preview
Go deeper on Impel Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Impel Pharmaceuticals.